Latham & Watkins Advised Evoke Pharma on Acquisition by QOL Medical

Latham & Watkins Advised Evoke Pharma on Acquisition by QOL Medical

Pharma, Inc. (NASDAQ: EVOK) (Evoke), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, and QOL Medical, LLC (QOL Medical), a privately held biopharmaceutical company specializing in treatments for GI and rare diseases, have announced that they have entered into a definitive agreement pursuant to which QOL Medical will acquire Evoke for US$11 per share in cash at closing. The transaction has been unanimously approved Evoke by the Boards of Directors of both companies and will be conducted via a tender offer.

The Latham & Watkins LLP team was led by Daniel Rees (Partner), San Diego (Partner), Matthew Bush (Partner), Holly Bauer (Partner), Betty Pang (Partner), Pardis Zomorodi (Partner), Christine Mainguy (Partner), Steven Chinowsky (Partner) and Heather Deixler (Partner) with Anthony Gostanian (Counsel), Chad Jennings (Counsel), Darryl Steensma (Counsel), Robert Yeh (Counsel) and Lindsey Utrata (Counsel), Shannon Cheng (Associate), Amy Lutfi (Associate), Ashley Campfield (Associate), Joanna Yam (Associate), Shelby Harrison (Associate), Julie Voorhes (Associate), Tessa Young (Associate), Kristina Funahashi (Associate) and Kathryn Parsons-Reponte (Associate) with Chloe Wallance (Assistance).

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.